BIBProShares Ultra Nasdaq Biotechnology
Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.
By ProShares · Launched 2010
Annual Cost
0.95%
#5,033 of 6,040 · expensive
Fund Size
$101M
#3,083 of 6,040 · mid-size
Return (1Y)
+102.4%
Track Record
16 years
#763 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$16,767+67.7%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Leveraged
Sector
Health careIndex tracked
Nasdaq Biotechnology Index
Holdings
By weightConcentration
synthetic exposure — holdings shown are derivatives collateral, not the fund's positions
Gilead Sciences, Inc.
6.5%
N/A
6.3%
Vertex Pharmaceuticals, Inc.
6.3%
Amgen, Inc.
6.2%
Regeneron Pharmaceuticals, Inc.
4.1%
N/A
3.6%
N/A
2.9%
N/A
2.9%
N/A
2.6%
Alnylam Pharmaceuticals, Inc.
2.2%
Asset allocation
Stocks
66.1%
Other
22.2%
Cash
11.7%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
43.1%High
Year-on-year price swings
Max drawdown
-66.2%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.77Decent risk-adjusted returns
Sortino (3Y)
1.12Good downside protection
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.
- Strategy
- Invests in financial instruments to achieve daily returns consistent with the Daily Target, targeting 2x exposure to U.S. and non-U.S. biotechnology and pharmaceutical companies based on market capitalization. Uses derivatives like swap agreements for leveraged exposure and rebalances daily to maintain target exposure.
- Inception date
- April 6, 2010
- Fund family
- ProShares
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save BIB to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18